




Fast Diagnosis When it Matters Most

■ Xpert® Flu & Xpert Flu/RSV

CLIA Waived



US-IVD. *In Vitro* Diagnostic Medical Device. Not available in all countries.



## Xpert® Xpress Flu Xpert® Xpress Flu/RSV



### The Need

- In patients of all ages, influenza and RSV often present with similar clinical symptoms, making it difficult to differentiate between the two infections<sup>1</sup>
- Sensitivities of rapid EIA Flu tests range from 50–70%<sup>2</sup>
- Sensitivities of rapid antigen RSV tests average 29% in adults<sup>3</sup>
- Both rapid EIA and antigen manufacturers suggest confirming negative results with RT-PCR or culture<sup>2</sup>
- Rapid RSV tests may have age limitations<sup>4</sup>



### The Solution

- Accurate and reliable detection of Flu A, Flu B and RSV in as soon as 20 minutes\*
- Enables healthcare providers to quickly deliver targeted therapies
- Streamlines laboratory operations
- Improves patient satisfaction



### The Impact

Single-test confidence will accelerate your laboratory's workflow with on-demand, random-access flexibility. Combine performance with the capability to run other Xpert® tests (including GBS, MRSA, C. difficile, CT/NG, and MTB/RIF) on Cepheid's GeneXpert® System to achieve proven productivity increases in overall laboratory service.<sup>5-9</sup>

#### Be Proactive

- Achieve rapid results and improve patient management
- Early assay termination option: deliver positive results in as soon as 20 minutes\* and negative results in 30 minutes
- Quickly deliver targeted therapies and increase peace of mind for patients

Coverage, plus  
Accuracy, plus  
Peace of mind


That's the PCR<sup>plus</sup> advantage.  
From Cepheid.




## Impact on Outpatient Pathway

### Improving Patient Satisfaction

Xpert® Xpress Flu and Xpert® Xpress Flu/RSV provides medically actionable and timely information to clinicians to support improved patient management and antibiotic and antiviral stewardship.



## Impact on Patient Admission & Management at Emergency Department



\* With early assay termination (EAT) for positive Flu or for positive RSV only. Reporting negatives and combined Flu and RSV results in 30 minutes.

# Workflow: 3 Easy Steps

1

Obtain specimen stored in appropriate transport medium or saline



2

Transfer sample to cartridge



3

Insert cartridge and start test



CATALOG INFORMATION		
Xpert® <b>Xpress</b> Flu	10 tests	XPRSFLU-10
Xpert® <b>Xpress</b> Flu/RSV	10 tests	XPRSFLU/RSV-10

COLLECTION KITS			CATALOG INFORMATION
Cepheid Nasal Collection Kits	50 kits		3C064N
Nasopharyngeal Swab & UTM Collection Kits	50 kits		3C057N

CPT CODE INFORMATION		CPT CODE
Xpert® <b>Xpress</b> Flu	Influenza virus, for multiple types or sub-types, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, first 2 types or sub-types	<b>MODERATE:</b> 87502 <b>CLIA-WAIVED:</b> 87502-QW
Xpert® <b>Xpress</b> Flu/RSV	Respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3–5 targets	<b>MODERATE:</b> 87631 <b>CLIA-WAIVED:</b> 87631-QW

## References:

- 1 Falsey AR, Walsh EE. Respiratory Syncytial Virus Infection in Adults. Clin Microbiol Rev. 2000 Jul; 13.
- 2 CDC. Guidance for Clinicians on the Use of Rapid Influenza Diagnostic Tests. Accessed Aug 2020. [http://www.cdc.gov/flu/professionals/diagnosis/clinician\\_guidance\\_rid\\_t.htm](http://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_rid_t.htm)
- 3 Chartrand C, et al. Diagnostic Accuracy of Rapid Antigen Detection Tests for Respiratory Syncytial Virus Infection: Systematic Review and Meta-analysis. J Clin Microbiol. 2015 Dec;53(12):3738-49.
- 4 BD Veritor™ System – For Rapid Detection of Flu A+B. Package Insert. DB. Dublin, Ireland. 2014.
- 5 Morgan MG. The Perfect Storm. Cepheid Impact. 2012 Jun;2:4-7.
- 6 Parada JP. Increase Revenue and Improve Patient Safety. Cepheid Impact. 2012 Jun;2:8-11.
- 7 El Helali N. Less Uncertainty - Better Safety - More Healthy Newborns. Cepheid Impact. 2012 Jul;3:4-7.
- 8 Haynes L. The C. difficile Challenge. Cepheid Impact. 2012 Jul;3:10-15.
- 9 Parada JP. Improving Patient Safety. Cepheid Impact. 2012 Oct;4:8-11.

US-IVD. *In Vitro* Diagnostic Medical Device. Not available in all countries.

## CORPORATE HEADQUARTERS

904 Caribbean Drive  
Sunnyvale, CA 94089 USA

TOLL FREE +1.888.336.2743  
PHONE +1.408.541.4191  
FAX +1.408.541.4192

## EUROPEAN HEADQUARTERS

Vira Solelh  
81470 Maurens-Scopont France

PHONE +33.563.82.53.00  
FAX +33.563.82.53.01  
EMAIL [cepheid@cepheideurope.fr](mailto:cepheid@cepheideurope.fr)

[www.Cepheid.com](http://www.Cepheid.com)

© 2022 Cepheid. 0618-04